TH134757A - Pharmaceutical constituents containing linagliptin and SGLT2 inhibitors and their use may be selected. - Google Patents
Pharmaceutical constituents containing linagliptin and SGLT2 inhibitors and their use may be selected.Info
- Publication number
- TH134757A TH134757A TH1101001517A TH1101001517A TH134757A TH 134757 A TH134757 A TH 134757A TH 1101001517 A TH1101001517 A TH 1101001517A TH 1101001517 A TH1101001517 A TH 1101001517A TH 134757 A TH134757 A TH 134757A
- Authority
- TH
- Thailand
- Prior art keywords
- pharmaceutical
- linagliptin
- substances
- pharmaceutical constituents
- sglt2 inhibitors
- Prior art date
Links
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 title abstract 3
- 229960002397 Linagliptin Drugs 0.000 title abstract 3
- 239000000470 constituent Substances 0.000 title abstract 3
- 102100016749 SLC5A2 Human genes 0.000 title 1
- 101710040674 SLC5A2 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000126 substance Substances 0.000 claims abstract 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drugs Drugs 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000005426 pharmaceutical component Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutic aid Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Abstract
DC60 (15/03/56) การประดิษฐ์นี้เกี่ยวข้องกับองค์ประกอบเชิงเภสัชกรรมที่ประกอบรวมด้วยลิแนกลิพทิน (linagliptin) หรือเกลือที่เป็นที่ยอมรับเชิงเภสัชกรรมของสารเหล่านี้ ในฐานะที่เป็นส่วนผสม เชิงเภสัชกรรมที่มีฤทธิ์ส่วนผสมแรก และ 1-คลอโร-4-(เบตา-D-กลูโคไพแรนอส-1-อิล)-2-[4-(S)- เตตราไฮโดรฟิวแรน-3-อิลออกซี)-เบนซิล]-เบนซีน ซึ่งเป็นส่วนผสมเชิงเภสัชกรรมที่มีฤทธิ์มีส่วนผสม ที่สอง และส่วนเติมเนื้อยาหนึ่งชนิดหรือมากกว่า รูปแบบยาของสารเหล่านี้ สารเตรียมของสารเหล่านี้ การใช้ของสิ่งเหล่านี้ และวิธีการรักษาโรคทางเมแทบอลิซึม (metabolic disorder) การประดิษฐ์นี้เกี่ยวข้ององค์ประกอบเชิงเภสัชกรรมที่ประกอบรวมด้วยลิแนกลิพทิน, รูปแบบยา เชิงเภสัชกรรม, การเตรียมสาร, การใช้สารและวิธีสำหรับการรักษาโรคทางเมแทบอลิซึม สิทธิบัตรยา DC60 (15/03/56) This invention relates to pharmaceutical constituents incorporating linagliptin. (linagliptin) or a chemically acceptable salt of these substances. As a mixture The first active ingredient and 1-Chloro-4- (Beta-D-Glucopyranos-1-Il) -2- (4- (S) - Tetrahydrofurae. N-3-iloxi) -benzyl) -benzene Which is an active pharmaceutical ingredient with a second and one or more drug additives. Dosage forms of these substances Preparations of these substances The use of these And methods of treatment of metabolic disorder. This invention relates to the pharmaceutical constituents comprising linacliptin, pharmaceutical formulation, preparation, use of the substance and method for the Treatment of metabolic diseases, drug patents
Claims (2)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH134757A true TH134757A (en) | 2014-06-11 |
| TH134757B TH134757B (en) | 2014-06-11 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123270T1 (en) | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASE TISSUE OXYGENATION | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| NZ708593A (en) | Novel pyrazole derivative | |
| EA201100030A1 (en) | PYRAZOL COMPOUNDS 436 | |
| WO2012007869A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| EA200901133A1 (en) | DERIVATIVES OF DIANILINOPYRIMIDINE AS KEEIN INHIBITORS WEE1, PHARMACEUTICAL COMPOSITION AND USE | |
| MA32200B1 (en) | New formulations, tablets consisting of these formulas, their use and method of preparation | |
| WO2012007877A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| BR112015015477A2 (en) | 2,3-dihydro-isoindol-1-one derivatives and methods of using them as btk inhibitors | |
| BR112014009087A2 (en) | xylitol stabilized etanercept formulations | |
| EA200970967A1 (en) | OXADIAZOLE-SUBSTITUTED DERIVATIVES INDASOLS FOR APPLICATION AS AGONISTS SPHINGOZIN 1-PHOSPHATE (SIP) | |
| DE602006012725D1 (en) | Glucagonone receptor agonists, their preparation and their therapeutic use | |
| EA201100032A1 (en) | PYRIDINE COMPOUNDS | |
| EA201400358A1 (en) | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTAN-3-CARBOXAMIDE INHIBITORS KATEPSIN C | |
| EA201400567A1 (en) | NEW CYCLOGEXYLAMINE DERIVATIVES THAT HAVE AN AGONISTIC ACTIVITY WITH RESPECT TO β2 ADRENERGIC RECEPTOR AND ANTAGONISTIC ACTIVITY WITH RESPECT TO MUSCARINO RECEPTOR | |
| EA201490471A1 (en) | PYRIDAZINOUS COMPOUNDS AND THEIR APPLICATION AS DAAO INHIBITORS | |
| WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
| ATE487720T1 (en) | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | |
| NZ607580A (en) | N-heteroaryl compounds | |
| EA201001747A1 (en) | BENZOXASINIC DERIVATIVES, ACTING AS AN AGONIST BETA-2-ADRENOCEPTOR, FOR THE TREATMENT OF RESPIRATORY DISORDERS | |
| DE602006015509D1 (en) | Glucagonone receptor agonists, their preparation and their therapeutic use | |
| WO2013061004A8 (en) | Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
| MA32406B1 (en) | Compounds containing tricyclic azotes and their use as antibacterials | |
| CL2020001420A1 (en) | Procedure for the preparation of (3s) -3- (4-chloro-3 - {[(2s, 3r) -2- (4-chlorophenyl) -4,4,4-trifluoro-3-methylbutanoyl] amino} phenyl) -3-cyclopropylpropanoic acid and its crystalline form for use as an active pharmaceutical ingredient. | |
| EA201300857A1 (en) | PYRAZOLES AS AN ANTAGONISTS CRTH2 |